


Please type a plus sign (+) inside this box → ☐



RECEIVED  
 MAY 30 2003  
 TECH CENTER 1600 2000


Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b> Application Number    09/443,863 Filing Date            November 19, 1999 First Named Inventor    PARIKH Group Art Unit          1615 Examiner Name         G. Kishore Attorney Docket Number   401930/SkyePharma		
Sheet	1	of	4		

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A 1	3981984		Signorino	9/21/1976	
	A 2	3983140		Endo et al.	9/28/1976	
	A 3	4006025		Swank et al.	2/1/1977	
	A 4	4231938		Monaghan et al.	11/4/1980	
	A 5	4294916		Postle et al.	10/13/1981	
	A 6	4346227		Terahara et al.	8/24/1982	
	A 7	4448784		Glamkowski et al.	5/15/1984	
	A 8	4450171		Hoffman et al.	5/22/1984	
	A 9	4475919		Woznicki et al.	10/9/1984	
	A 10	4543370		Porter et al.	9/24/1985	
	A 11	4643894		Porter et al.	2/17/1987	
	A 12	4683256		Porter et al.	7/28/1987	
	A 13	4704295		Porter et al.	11/3/1987	
	A 14	4727077		Haga et al.	2/23/1988	
	A 15	4739073		Kathawala	4/19/1988	
	A 16	4802924		Woznicki et al.	2/7/1989	
	A 17	4828841		Porter et al.	5/9/1989	
	A 18	4897402		Duggan et al.	1/30/1990	
	A 19	4904646		Karanevsky et al.	2/27/1990	
	A 20	4906624		Chucholowski et al.	3/6/1990	
	A 21	4906657		Roth	3/6/1990	
	A 22	4920109		Onishi et al.	3/24/1990	
	A 23	4923861		Picard et al.	5/8/1990	
	A 24	4929620		Chucholowski	5/29/1990	
	A 25	4939143		Regan et al.	7/3/1990	
	A 26	4940727		Inamine et al.	7/10/1990	
	A 27	4940800		Bertolini et al.	7/10/1990	
	A 28	4946860		Morris et al.	8/7/1990	
	A 29	4946864		Prugh et al.	8/7/1990	
	A 30	4950675		Chucholowski	8/21/1990	
	A 31	4957940		Roth	9/18/1990	
	A 32	4963538		Duggan et al.	10/16/1990	
	A 33	4968693		Joshua et al.	11/6/1990	
	A 34	4970231		Lee et al.	11/13/1990	
	A 35	4992429		Ullrich et al.	2/12/1991	
	A 36	4994494		Regan et al.	2/19/1991	
	A 37	4996234		Regan et al.	2/26/1991	
	A 38	4997837		Chucholowski et al.	3/5/1991	
	A 39	5001128		Neuenschwander et al.	3/19/1991	
	A 40	5001144		Regan et al.	3/19/1991	

Examiner Signature	Date Considered
--------------------	-----------------

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number 09/443,863  
Filing Date November 19, 1999  
First Named Inventor PARIKH  
Group Art Unit 1615  
Examiner Name G. Kishore  
Attorney Docket Number 401930/SkyePharma

RECEIVED  
MAY 30 2003  
TECH CENTER 1500 2003

### U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A 4 1	5017716		Karnewsky et al.	5/21/1991	
	A 4 2	5021453		Joshua et al.	6/4/1991	
	A 4 3	5025000		Karnewsky	6/18/1991	
	A 4 4	5081136		Bertolini et al.	1/14/1992	
	A 4 5	5091378		Karnewsky et al.	2/25/1992	
	A 4 6	5091386		Kessler et al.	2/25/1992	
	A 4 7	5098931		Duggan et al.	3/24/1992	
	A 4 8	5102911		Lee et al.	4/7/1992	
	A 4 9	5112857		Vickers	5/12/1992	
	A 5 0	5116870		Smith et al.	5/26/1992	
	A 5 1	5130306		Duggan et al.	7/14/1992	
	A 5 2	5132312		Regan et al.	7/21/1992	
	A 5 3	5135935		Alberts et al.	8/4/1992	
	A 5 4	5166171		Jendralla et al.	11/24/1992	
	A 5 5	5182298		Helms et al.	1/26/1993	
	A 5 6	5196440		Bertolini et al.	3/23/1993	
	A 5 7	5202327		Robl	4/13/1993	
	A 5 8	5250435		Cover et al.	10/5/1993	
	A 5 9	5256689		Chiang	10/26/1993	
	A 6 0	5260332		Dufresne	11/9/1993	
	A 6 1	5262435		Joshua et al.	11/16/1993	
	A 6 2	5273995		Roth	12/28/1993	
	A 6 3	5276021		Karnewsky et al.	1/4/1994	
	A 6 4	5283256		Dufresne et al.	2/1/1994	
	A 6 5	5286895		Harris et al.	2/15/1994	
	A 6 6	5302604		Byrne et al.	4/12/1994	
	A 6 7	5317031		MacConnell et al.	5/31/1994	
	A 6 8	5356896		Kabadi et al.	10/18/1994	
	A 6 9	5369125		Berger et al.	11/29/1994	
	A 7 0	5385932		Vickers	1/31/1995	
	A 7 1	5435840		Hilborn	7/25/1995	
	A 7 2	5470581		Grillo et al.	11/28/1995	
	A 7 3	5622985		Olukotun et al.	4/22/1997	
	A 7 4	5700471		End et al.	12/23/1997	
	A 7 5	5785976		Westesen et al.	7/28/1998	
	A 7 6	6027747		Terracol et al.	2/22/2000	
	A 7 7	6042847		Kerč et al.	3/28/2000	
	A 7 8	6068854		Wunderlich et al.	5/30/2000	
	A 7 9	6074670		Stamm et al.	6/13/2000	
	A 8 0	6096338		Lacy et al.	8/1/2000	


Examiner Signature

Date Considered

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/443,863		
		Filing Date	November 19, 1999		
		First Named Inventor	PARIKH		
		Group Art Unit	1615		
Examiner Name	G. Kishore				
Sheet	3	of	4	Attorney Docket Number	401930/SkyePharma

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
	A 8 1	6180138		Engl et al.	1/30/2001	
	A 8 2	RE36520		Smith et al.	1/18/2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	A 8 3	CA	2048395		Pan, Henry Y.	2/24/1992		
	A 8 4	EP	0 114 027		Sandoz-Patent-GMBH	1/7/1988		
	A 8 5	EP	0 304 063		Nissan Chemica Industries Ltd.	11/30/1994		
	A 8 6	EP	0 455 042		E.R. Squibb & Sons, Inc.	11/6/1991		
	A 8 7	EP	0 475 148		E.R. Squibb & Sons, Inc.	3/18/1992		
	A 8 8	EP	0 687 172		Pharmacia AB	12/20/1995		
	A 8 9	EP	0 793 958		Durachemie GmbH & Co.	2/28/1997		X*
	A 9 0	EP	0 807 431		F. Hoffmann-LA Roche AG	4/19/1997		
	A 9 1	EP	0 904 781		Sherman, Bernard Charles	3/31/1999		
	A 9 2	WO	00/16749		CLL Pharma	3/30/2000		
	A 9 3	WO	00/30616		RTP Pharma Inc.	6/2/2000		
	A 9 4	WO	00/37057		Abbott Laboratories	6/29/2000		
	A 9 5	WO	00/37078		Bayer Aktiengesellschaft	6/29/2000		
	A 9 6	WO	00/40220		Korea Research Institute of Chem. Tech.	7/13/2000		
	A 9 7	WO	00/45817		Astrazeneca UK Ltd.	8/10/2000		
	A 9 8	WO	01/80828		RTP Pharma Inc.	11/1/2001		
	A 9 9	WO	97/13503		The Penn State Research Foundation	4/17/1997		
	A 1 0 0	WO	98/31361		Laboratories Fournier	7/23/1998		
	A 1 0 1	WO	98/35666		Nanosystems LLC	8/20/1998		
	A 1 0 2	WO	99/65469		RTP Pharma Inc.	12/23/1999		
	A 1 0 3	WO	99/04761		Pharmacia & Upjohn AB	2/4/1999		
	A 1 0 4	WO	99/39700		Vector-Pharma	8/12/1999		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A 1 0 5	D. FLEISCHER et al., "Drug, Meal & Formulation Interactions Influencing Drug Absorption After Oral Administration," Clin. Pharmacokinetic, 1999, Mar:36(3), pp. 233-264		
	A 1 0 6	FARNIER et al., "Effect of Combined Fluvastatin-Fenofibrate Therapy Compared with Fenofibrate Monotherapy in Severe Primary Hypercholesterolemia," The Amer. J. of Cardiology, Vol. 85, Jan 1, 2000, pp. 53-57		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	4	of	4
-------	---	----	---

Application Number	09/443,863
Filing Date	November 19, 1999
First Named Inventor	PARIKH
Group Art Unit	1615
Examiner Name	G. Kishore
Attorney Docket Number	401930/SkyePharma

[illegible]Date  
Considered

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).